| Name | CCR4 antagonist 2 |
|---|---|
| Synonyms |
CCR4 antagonist 2,CCR-4 antagonist 2
1H-Pyrazolo[3,4-b]pyrazine-3-carbonitrile, 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-5-methyl-1-cyclohexen-1-yl] |
| Description | CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues.CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 40 nM (Ca2+flux); 70 nM (CTX) (CCR4 antagonist 2)[1] |
| References |
| Molecular Formula | C26H28Cl2N6O |
|---|---|
| Molecular Weight | 511.45 |